Actively Recruiting
Evaluating XEN1101 as an Additional Treatment for Primary Generalized Tonic-Clonic Seizures A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Led by Xenon Pharmaceuticals Inc. · Updated on 2026-11-02
160
Participants Needed
141
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating XEN1101 as an additional treatment for people with primary generalized tonic-clonic seizures PGTCS in this Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. The study aims to assess the clinical efficacy, safety, and tolerability of XEN1101 in subjects diagnosed with generalized epilepsy who are currently taking 1 to 3 anti-seizure medications ASMs. Participants must have probable or possible PGTCS and meet specific inclusion criteria. Participants aged 12 years and older will be randomly assigned to receive either XEN1101 or a placebo. Those 18 years and older will receive 25 mg of XEN1101 or placebo daily, while those between 12 and under 18 years may receive 15 mg, 25 mg, or placebo once daily with an evening meal. The study includes a baseline period lasting up to 9.5 weeks to monitor seizure frequency, followed by a 12-week double-blind treatment period. After completing this phase, participants can enter an open-label extension study to continue XEN1101 treatment or join an 8-week post-treatment follow-up. Throughout the study, participants will keep accurate seizure diaries and undergo assessments to measure the median percent change in monthly PGTCS frequency. The study will also monitor safety and tolerability during treatment. Those who do not continue into the extension phase will have follow-up visits for 8 weeks after treatment ends. Overall, the trial involves multiple visits and careful monitoring to evaluate the impact of XEN1101 as adjunctive therapy over several months.
CONDITIONS
Brief Title
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Research Team
X
Xenon Medical Affairs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here